Chimeric Antigen Receptor T Cell Therapy versus Hematopoietic Stem Cell Transplantation: An Evolving Perspective
Author:
Publisher
Elsevier BV
Subject
Transplantation,Cell Biology,Hematology,Molecular Medicine,Immunology and Allergy
Reference83 articles.
1. Indications for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation;Majhail;Biol Blood Marrow Transplant,2015
2. Hematopoeitic cell transplantation and CAR T-cell therapy: complements or competitors?;Goldsmith;Front Oncol,2020
3. Indications for hematopoietic cell transplantation and immune effector cell therapy: guidelines from the American Society for Transplantation and Cellular Therapy;Kanate;Biol Blood Marrow Transplant,2020
4. Use of chimeric antigen receptor T cell therapy in clinical practice for relapsed/refractory aggressive B cell non-Hodgkin lymphoma: an expert panel opinion from the American Society for Transplantation and Cellular Therapy;Jain;Biol Blood Marrow Transplant,2019
5. CAR T-cell therapy for large B-cell lymphoma—who, when, and how?;Roschewski;N Engl J Med,2022
Cited by 7 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Clonal Hematopoiesis is Associated With Severe Cytokine Release Syndrome in Patients Treated With Chimeric Antigen Receptor T-Cell (CART) Therapy;Transplantation and Cellular Therapy;2024-09
2. The first case of multiple myeloma treated with ASCT followed by Anti-BCMA CAR-T cells using retrovirus vector: A case report;Heliyon;2024-09
3. The First Case of Multiple Myeloma Treated With ASCT followed by Anti-BCMA CART Cells using Retroviral Vector;2024-01-19
4. Gene targeted and immune therapies for nodal and gastrointestinal follicular lymphomas;World Journal of Gastroenterology;2023-12-28
5. Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3;Journal for ImmunoTherapy of Cancer;2023-08
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3